INVO Bioscience, Inc. - 10-Q Summary (Q1 2009)
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2009. INVO Bioscience, Inc. (formerly Emy's Salsa Aji Distribution Company, Inc. following a reverse merger in December 2008) is a development-stage company focused on commercializing the INVOcell, a medical device designed to simplify in vitro fertilization (IVF) procedures. The company obtained CE Marking in May 2008, allowing sales in the European Economic Area and other international markets, but has not yet received FDA clearance for the U.S. market.
Key Financial Metrics
| Metric | Q1 2009 | Q1 2008 |
|---|---|---|
| Revenue | $36,815 | $0 |
| Gross Margin | $16,146 (43.8%) | $0 |
| Net Loss | $(651,054) | $(41,312) |
| Cash Flow from Operations | $(280,965) | $(7,226) |
| Cash and Equivalents (End of Period) | $9,751 | $0 |
| Total Current Liabilities | $1,296,992 | $891,660 |
| Working Capital Deficiency | $(1,099,786) | Not Reported |
Debt and Liquidity: The company holds a $50,000 line of credit (fully utilized) and has related party notes totaling $171,462 ($75,000 current, $96,462 long-term). Accounts payable increased significantly to $556,804.
Material Changes vs. Prior Period
- Revenue Generation: The company generated its first commercial revenue of $36,815 in Q1 2009, compared to zero in Q1 2008, driven by international shipments to distributors and physicians.
- Expense Surge: Selling, General, and Administrative (SG&A) expenses jumped from $39,233 to $656,900. This increase is attributed to hiring six full-time employees (up from three), significant international travel ($70,000) for market expansion, and costs associated with being a public company ($159,000).
- Loss Expansion: Net loss widened to $(651,054) from $(41,312) due to the substantial increase in operating expenses outpacing initial revenue.
- Liabilities: Current liabilities increased by approximately $405,000, primarily due to a rise in accounts payable and a new $75,000 short-term loan from the CEO.
Outlook, Risks, and Management Commentary
Going Concern: The filing explicitly states that the company's recurring losses, negative cash flows, and working capital deficiency raise substantial doubt about its ability to continue as a going concern. Continued operations are dependent on raising additional capital.
Capital Needs: Management estimates a monthly burn rate of approximately $200,000. The company is actively seeking up to $5 million in capital through a private placement. Failure to secure funding may force the company to curtail operations or downsize.
Regulatory Status: The company is pursuing FDA 510(k) clearance for the U.S. market, with a target of 2010, though no assurance is given. International sales remain the sole revenue source.
Internal Controls: Management concluded that disclosure controls and procedures were ineffective as of March 31, 2009, citing a material weakness in internal control over financial reporting due to limited resources and staff.
Investor Verification Checklist
- Cash Runway: Verify the current cash balance (reported as $9,751) against the stated monthly burn rate of $200,000 to assess immediate liquidity risk.
- Capital Raise Status: Confirm the status of the proposed $5 million private placement and the $205,000 remaining due from Lionshare Ventures LLC.
- Related Party Transactions: Review the terms of the $171,462 in loans from the CEO and President, including interest rates and repayment schedules.
- Revenue Sustainability: Assess the scalability of the $36,815 revenue, noting the high cost of sales (56%) attributed to small lot sizes and shipping.
- Internal Controls: Evaluate the remediation plan for the identified material weakness in financial reporting controls.